SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PAGANELLI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.931
EU - Europa 2.922
AS - Asia 2.150
SA - Sud America 257
AF - Africa 25
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.298
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.902
PL - Polonia 1.263
CN - Cina 754
SG - Singapore 748
IT - Italia 402
TR - Turchia 328
UA - Ucraina 278
DE - Germania 254
SE - Svezia 252
BR - Brasile 223
GB - Regno Unito 213
ID - Indonesia 99
VN - Vietnam 82
IE - Irlanda 48
NL - Olanda 43
RU - Federazione Russa 29
HK - Hong Kong 24
JO - Giordania 23
AT - Austria 22
BE - Belgio 22
FR - Francia 22
KR - Corea 22
CA - Canada 20
FI - Finlandia 16
RO - Romania 14
IN - India 13
AR - Argentina 9
AU - Australia 9
VE - Venezuela 8
PK - Pakistan 7
PT - Portogallo 7
AE - Emirati Arabi Uniti 6
BD - Bangladesh 6
CZ - Repubblica Ceca 6
CO - Colombia 5
EC - Ecuador 5
GR - Grecia 5
IQ - Iraq 5
JP - Giappone 5
BG - Bulgaria 4
DZ - Algeria 4
MA - Marocco 4
RS - Serbia 4
SC - Seychelles 4
ZA - Sudafrica 4
AZ - Azerbaigian 3
BO - Bolivia 3
CH - Svizzera 3
DK - Danimarca 3
IR - Iran 3
LT - Lituania 3
MX - Messico 3
MY - Malesia 3
PE - Perù 3
TN - Tunisia 3
TW - Taiwan 3
AL - Albania 2
CY - Cipro 2
EG - Egitto 2
EU - Europa 2
GA - Gabon 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
ES - Italia 1
GE - Georgia 1
GL - Groenlandia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KE - Kenya 1
KH - Cambogia 1
KZ - Kazakistan 1
MK - Macedonia 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 15.298
Salva come PNG Salva come JPEG
Città #
Fairfield 1.499
Warsaw 1.259
Woodbridge 1.181
Ashburn 829
Houston 752
Seattle 605
Chandler 551
Santa Clara 536
Jacksonville 495
Wilmington 495
Cambridge 486
Ann Arbor 380
Singapore 347
Izmir 298
Princeton 183
Nanjing 170
Milan 126
San Diego 106
Beijing 102
Boardman 101
Jakarta 97
Dearborn 94
Dong Ket 82
Menlo Park 69
Nanchang 67
Ferrara 52
London 50
Los Angeles 48
Hebei 45
Falls Church 42
Shenyang 38
Bologna 32
Council Bluffs 30
Mountain View 30
Shanghai 29
Tianjin 29
Changsha 25
Jiaxing 25
Kunming 24
Redwood City 24
Washington 23
Brussels 22
Norwalk 22
Hong Kong 20
Orange 19
Nuremberg 18
Rome 17
Scottsdale 16
Jinan 15
Fuzhou 14
Addison 13
Seongnam 13
São Paulo 13
Helsinki 12
New York 12
Vienna 12
Bremen 11
Toronto 11
Zhengzhou 11
Belo Horizonte 10
Tappahannock 10
Chicago 9
Guangzhou 9
Indiana 9
Phoenix 9
Hefei 8
Hounslow 8
Kilburn 8
Poggio Renatico 8
Frankfurt am Main 7
Lanzhou 7
Simi Valley 7
Cesena 6
Changchun 6
Dublin 6
Forlimpopoli 6
North Bergen 6
Putian 6
Redmond 6
Seoul 6
Walnut 6
Amsterdam 5
Castenaso 5
Edinburgh 5
Hangzhou 5
Porto Alegre 5
Pune 5
Rio de Janeiro 5
San Mateo 5
Amman 4
Baghdad 4
Brasília 4
Campinas 4
Ilmenau 4
Monmouth Junction 4
Rio De Janeiro 4
Santo André 4
Tokyo 4
Algiers 3
Buenos Aires 3
Totale 11.972
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors 390
Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival 295
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images 226
Positron emission tomography in the diagnostic work-up of screening-detected lung nodules 220
Development of sentinel node localization and ROLL in breast cancer in Europe 212
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 207
A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions 199
Improper use of "radioguided occult lesion localization" (ROLL) technique leads to misleading conclusions 198
Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging 184
A novel radioguided surgery technique exploiting β- decays 178
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 174
Early use of abiraterone and radium-223 in metastatic prostate cancer 173
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice 170
Intramedullary spinal cord metastases from breast cancer: Detection with 18F-FDG PET/CT 167
Atypical primary pulmonary meningioma: A report of a case suspected of being a lung metastasis 162
Local accelerated radionuclide breast irradiation: Avidin-biotin targeting system 160
AvidinOX (TM) for highly efficient tissue-pretargeted radionuclide therapy 146
Radioimmunotherapy in brain tumors 143
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET 140
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study 135
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 135
A parathyroid carcinoma within a cold thyroid nodule 133
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas 132
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 131
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: Efficacy profile, safety, and quality of life 127
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors 120
68Ga- DOTA0-Tyr3octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours 116
Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening 115
[18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning 114
Nuclear medicine in the clinical management (ROLL, SNB, and PET) 114
Yttrium-labelled peptides for therapy of NET 112
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status 111
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 111
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors 110
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 109
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC 108
Sentinel lymph node biopsy in pregnant patients with breast cancer 108
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers 108
Long-term results of PRRT in advanced bronchopulmonary carcinoid 108
Neuroendocrine tumors 108
Intraoperative beta- detecting probe for radio-guided surgery of brain tumors 108
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 108
Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests 107
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors 104
Yttrium-based therapy for neuroendocrine tumors 103
SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes 103
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution 103
OXavidin for tissue targeting biotinylated therapeutics 102
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies 102
The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function 102
Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 102
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 101
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging 100
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin) 100
Hibernoma mimicking metastasis on positron emission tomography-computed tomography imaging: A misleading finding in oncologic patient follow-up 100
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma 99
Investigation of 90Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I-II clinical study 99
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients 98
Preoperative PET/CT in earlystage breast cancer: Is the TNM classification enough? 98
PET imaging of HER-2-positive tumours 97
Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? 97
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors 97
Therapeutic use of avidin is not hampered by antiavidin antibodies in humans 97
Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules 96
Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin 96
Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases 96
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours 96
Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: Results of a phase II study with 90Y-labeled biotin 96
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy 96
Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: Preliminary results 95
Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: Preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol 95
Preoperative FDG PET/CT in breast cancer patients: Where are we going? 94
Calculation of electron and isotopes dose point kernels with fluka Monte Carlo code for dosimetry in nuclear medicine therapy 94
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest 94
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy 93
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL) 93
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study 93
Hematologic toxicity and double autografting of stem cells after myeloablative activities of Yttrium-90-Ibritumomab tiuxetan 93
Treatment of a pituitary metastasis from a neuroendocrine tumour: Case report and literature review 93
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 93
Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas 92
Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma 92
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series 92
PET/CT and breast cancer subtypes 91
Is a SUV cut-off necessary in the evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 90
An unusual breast lesion: The ultrasonographic, mammographic, MRI and nuclear medicine findings of mammary hibernoma 90
Nonpalpable breast carcinomas: Long-term evaluation of 1,258 cases 89
Detection of a cardiac mass by [18F]FDG-PET/CT: A rare case 88
Financial aspects of sentinel lymph node biopsy in early breast cancer 87
Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment 87
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 87
Peptide Receptor Radionuclide Therapy (PRRT): clinical Application 86
Positron emission tomography for the detection of colorectal adenomas 86
Something more than estimating renal dosimetry 85
Computed tomography-guided preoperative radiotracer localization of nonpalpable lung nodules 85
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy 85
Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma 85
Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO) 85
Therapeutic schemes in 177Lu and 90Y-PRRT: Radiobiological considerations 84
Perspectives in the development of novel treatment approaches 83
Totale 11.891
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.943
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.349
Totale 98.292
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020967 0 0 0 0 0 0 0 0 345 238 274 110
2020/20212.527 106 174 139 228 178 422 132 309 86 315 180 258
2021/20221.303 84 64 35 47 21 133 82 142 69 160 107 359
2022/20231.635 184 44 75 181 195 246 122 151 190 12 148 87
2023/2024881 89 86 64 33 77 131 41 37 22 23 28 250
2024/20252.093 58 97 333 157 510 407 151 253 127 0 0 0
Totale 15.837